MedTrace Logo

Empiric Quinidine for Asymptomatic Brugada Syndrome

NCT00789165 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2020-02-13

No results posted yet for this study

Summary

The purpose of this study is to determine if quinidine therapy (not guided by the results of electrophysiologic studies) will reduce the long-term risk of arrhythmic events in asymptomatic Brugada Syndrome.

Conditions

Interventions

DRUG

quinidine

quinidine at highest tolerated dose. Expected doses are hydroquinidine 600 - 900 mg daily.

DRUG

no therapy

No therapy; this is not a placebo-controlled trial

Sponsors & Collaborators

  • International Registry of Asymptomatic Brugada Syndrome

    lead OTHER

Principal Investigators

  • Sami Viskin, M.D. · Tel Aviv Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2020-02-29
Completion
2020-12-31

Countries

  • United States
  • Germany
  • Israel
  • Italy
  • Japan
  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00789165 on ClinicalTrials.gov